Proteostasis Therapeutics Inc (PTI)

14.99
0.66 4.22
NASDAQ : Health Care
Prev Close 15.65
Open 15.65
Day Low/High 14.97 / 15.70
52 Wk Low/High 5.27 / 20.47
Volume 355.36K
Avg Volume 188.30K
Exchange NASDAQ
Shares Outstanding 19.18M
Market Cap 291.97M
Div & Yield N.A. (N.A)

Latest News

PTI Crosses Above Average Analyst Target

PTI Crosses Above Average Analyst Target

In recent trading, shares of Proteostasis Therapeutics Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $19.41/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Proteostasis Therapeutics Issues Mid-Year Corporate Update On Cystic Fibrosis Pipeline Programs

Proteostasis Therapeutics Issues Mid-Year Corporate Update On Cystic Fibrosis Pipeline Programs

Preliminary Biomarker Data Confirms PTI-428 Activity on CFTR mRNA in Human Subjects

Proteostasis Therapeutics Enters Oversold Territory (PTI)

Proteostasis Therapeutics Enters Oversold Territory (PTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

What You Need to Know About Biotech IPOs This Year

What You Need to Know About Biotech IPOs This Year

Here's the lowdown on the biotech companies that have come public this year.

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Data Presented at 13th Annual ECFS Basic Science Conference on Novel Therapies Targeting Cystic Fibrosis

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Company to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates on March 30, 2016

Patheon Completes Plan Of Arrangement

Patheon Completes Plan Of Arrangement

JLL/Delta Dutch Newco B.V. Announces Offering Of $500 Million Senior Notes Due 2022

JLL/Delta Dutch Newco B.V. Announces Offering Of $500 Million Senior Notes Due 2022

Offering will finance in part acquisition of Patheon Inc. and DPP Pharmaceuticals Business of DSM

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Global CDMO company combines DSM Pharmaceutical Products and Patheon

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading ...